Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of milvexian versus apixaban in atrial fibrillation
MOH_2023-09-19_012913Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of milvexian in Atrial fibrillation (AFib) (2 arms), sponsored by Janssen Pharmaceutical. Started Aug 2023; status: active, not recruiting.
02
Drugs
milvexian
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on MOH_2023-09-19_012913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-19_012913.